|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer
|
|
Louise Emmett, MD, MBChB, FRACP, FAANMS
|
| Louise Emmett unpacks the complexities of PSMA-targeted diagnostics and treatments in prostate cancer. She explores the significance of key trials such as ENZA-p, VISION, TheraP, PSMAfore, SPLASH, and ECLIPSE, examining the challenges in proving overall survival benefits and the potential of adaptive dosing strategies for improved patient outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
| Incorporating Lutetium-177 PSMA in the Multidisciplinary Setting |
Gordon Brown, DO, and Glen Gejerman, MD, MBA
Phillip Koo engages with Gordon Brown and Glen Gejerman to explore the multidisciplinary aspects of integrating a Lutetium-177 PSMA program into a large urology practice. |
|
|
|
|
|
|
|
|
|
|
| What is the Optimal Time for PSMA Radioligand Therapy? "Presentation" |
| A. Oliver Sartor, MD |
| At the 2024 UCSF-UCLA PSMA Conference, Oliver Sartor advocates for the early use of PSMA radioligand therapy in prostate cancer treatment, challenging the traditional reliance on castration and chemotherapy due to their significant side effects. |
|
|
|
|
|
|
|
|
|
|
|
| Enzalutamide and 177Lu-PSMA-617 in Poor-Risk Metastatic Castration-Resistant Prostate Cancer (mCRPC), a Randomized, Phase 2 Trial
|
| Louise Emmett, MBChB, FRACP, MD
|
| Louise Emmett presents on the ENZA-p trial, a phase 2 study of enzalutamide and 177Lu-PSMA-617 in poor-risk mCRPC, revealing promising results. Combining enzalutamide with adaptive-dosing, LuPSMA demonstrates enhanced anticancer activity, with longer PSA PFS and higher PSA response rates compared to enzalutamide alone. These findings suggest potential benefits for patients with metastatic castration-resistant prostate cancer and warrant further investigation in larger trials.
|
|
|
|
|
|
| 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist
|
| Megan Crumbaker, MBBS, Ph.D., FRACP
|
| Megan Crumbaker discusses 225-Actinium-PSMA-617 in the ProsTIC PCF Global Webinar 2023, highlighting its potential to overcome radiation resistance and treat micro-metastatic disease in prostate cancer. Although promising PSA response rates were present, concerns over toxicity, particularly xerostomia, were addressed, emphasizing the need for careful consideration of introducing this therapy, especially in patients with lower PSMA expression or resistance to other treatments like LuPSMA.
|
|
|
|
|
|
|
|
|
|
|
| Using Clinical Intelligence to Define First Line mCRPC Therapy
|
| Christopher Sweeney, MBBS
|
| Christopher Sweeney discusses the PSMAfore phase 3 trial emphasizing its strengths in documenting activity and allowing crossover in the control group. However, limitations include the modest endpoint of rPFS and the need for optimal dosing and long-term safety data. Dr. Sweeney underscores the importance of personalized treatment principles for metastatic prostate cancer, advocating for effective hormonal therapy and precision medicine based on individual patient profiles.
|
|
|
|
|
|
| The Current and Future Role of PSMA-Based Theranostics in Men with Advanced Prostate Cancer |
| Silke Gillessen Sommer, MD |
| Silke Gillessen Sommer discussed the current and future role of PSMA-based theranostics in advanced prostate cancer at the EAU 2023 congress. Highlighting the VISION trial, which showed improved overall survival with 177Lu-PSMA-617, she discussed its approval by the European Medicines Agency (EMA) in combination with ADT for patients previously treated with androgen receptor pathway inhibitors and taxane. |
|
|
|
|
|
| PSMA Radioligand Therapy: The VISION and TheraP Trials |
| Michael Morris, MD |
| Michael Morris presented findings from the VISION and TheraP trials at the 2024 PSMA conference. The VISION trial demonstrated that 177Lu-PSMA-617 plus standard of care significantly improved overall survival and radiographic progression-free survival compared to standard of care alone in PSMA-positive mCRPC patients. Predictive models from VISION identified parameters prognostic for clinical outcomes after 177Lu-PSMA-617. |
|
|
|
|
|
|
|
|
|
|
|
